Point of care C-reactive protein testing may be useful in guiding ...
Dec 6, 2024 · 1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations of COPD with no reduction in patient outcome Evidence Rating Level: 1 (Excellent) About 80% of patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to primary care are often given antibiotics that
RAMOSE Phase II trial finds promising results for osimertinib and ...
Dec 10, 2024 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...
Amivantumab plus lazertinib improves survival in EGFR-mutated …
Nov 27, 2024 · 1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer (NSCLC). 2. Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutated advanced NSCLC. Evidence Rating Level: 1 (Excellent) Study Rundown ...
Adjuvant durvalumab therapy improves survival in limited-stage …
Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small
MRI-informed biopsy recommendation reduces overdiagnosis in …
Oct 9, 2024 · 1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA but negative MRI reduced the diagnosis of clinically insignificant cancer. 2. MRI-negative men who did not undergo prostate biopsy did not have higher rates of incurable cancer diagnoses in follow-up screenings. Evidence Rating Level: 1
Radiotherapy with cetuximab or durvalumab for advanced HNSCC
Nov 18, 2024 · 1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 (non-significant). 2. Regarding safety, grade 3-4 adverse events occurred in 61% for durvalumab and 79% for cetuximab. Evidence Rating Level: 1 (Excellent) Study Rundown: Concurrent radiotherapy with cisplatin is the standard treatment for locoregionally advanced
Influenza vaccination may reduce secondary infection spread …
Dec 1, 2024 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Sep 9, 2024 · In-Depth [randomized controlled trial]: This phase 3, multicenter, open-label trial enrolled adults with stage IV clear-cell renal-cell carcinoma who had disease progression after treatment with immunotherapy and a VEGFR-TKI and randomized them (1:1) to belzutifan (n=374) or everolimus (n=372). Median follow-up time was 18.4 months for the first interim analysis and 25.7 months for the second ...
Multi-component sleep-mood group interventions may improve …
Nov 14, 2024 · 1. In this pilot randomized controlled trial, the Sleep Mood Intervention: Life Effectively (SMILE) intervention was associated with improvements in insomnia in university students. Evidence rating level: 1 (Excellent) Insomnia has a major burden on public health and can have serious long-term physical and mental health effects if left untreated.
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications